Clinical trials: Human Blood Cell Disorders
Hepatitis C
Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes
This proposal seeks to use DNA analyses to understand how racial and genetic factors influence interferon (treatment) response in HCV infection in African Americans.
- Trial name
- NCT00324389
- Testing
- Interferon alpha
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
This is a first-in-human (FIH) Phase 1/Phase 2 study for evaluating SAR445514 in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light chain amyloidosis (RRLCA).
- Trial name
- NCT05839626
- Testing
- SAR445514
- Where
- 16 sites in Australia, Belgium and 5 more
- Volunteers
- 32 people
- Sponsor
- Sanofi
Gaucher's Disease
Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease
OBJECTIVES: I. Transfer the human glucocerebrosidase (GC) gene into peripheral blood stem cells (PBSC) obtained from patients with type I Gaucher disease using a retroviral vector. II.
- Trial name
- NCT00004294
- Testing
- human glucocerebrosidase gene into autologous peripheral blood stem cells
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Center for Research Resources (NCRR)
Rheumatoid Arthritis
A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)
This 14-week study will observe the gene expression of certain immune cells in patients with rheumatoid arthritis who receive etanercept, infliximab, and adalimumab.
- Trial name
- NCT00724672
- Testing
- etanercept, infliximab, adalimumab
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, HCV Genotype 1
Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication
Open-label, single centre study evaluating efficacy and viral kinetics of combination PEG-IFNa2a and Ribavirin treatment on CHC genotype 1 patients, administered until viral clearance demonstrated between 4 - 12 weeks, then…
- Trial name
- NCT00152581
- Testing
- Pegylated interferon-alfa2a (Pegasys); ribavirin
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University College London Hospitals
Hepatitis C
Identification of Hepatitis C Virus (HCV) Specific T Cells
Nearly 175 million people worldwide are infected by Hepatitis C Virus (HCV), close to 3% of the global population. Contrary to other chronic infections such as HIV, clearance of HCV is possible.
- Trial name
- TETRA (NCT01534728)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Acute Leukemias, Burkitt's Lymphoma
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen.
- Conditions
- Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT02145039
- Testing
- Fludarabine, Cyclophosphamide, Total Body Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 or 24 weeks in adults with genotype 1 or 4…
- Trial name
- NCT02301936
- Testing
- LDV/SOF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus, Disorder of Immune Reconstitution
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Immune Reconstitution in Chronic HIV-1 Infected Patients
Combination antiretroviral therapy (ART) effectively suppresses viral replication, leading to a significant immune recovery and a dramatic reduction in the incidence of AIDS-defining events.
- Trial name
- NCT02648516
- Testing
- Conventional plus AAIT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing 302 Hospital
Multiple Myeloma, Acute Lymphoblastic Leukemia
A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.
About 90% of patients with haemato-oncologic malignancy lose their body muscle mass and also lose weight either due to chemotherapy induced nausea/vomiting or the high catabolic state due to fever, sepsis or chemotherapy.
- Conditions
- Multiple Myeloma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00300664
- Testing
- Human Growth hormone
- Volunteers
- 150 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Anal Dysplasia, Human Papillomavirus
The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. Infection by certain high-risk oncogenic types of HPV (HR-HPV) is the major cause of several cancers in men, notably squamous cell carcinoma…
- Conditions
- Anal Dysplasia, Human Papillomavirus, Anal Cancer
- Trial name
- HPV-SAVE (NCT02503111)
- Testing
- The Hyfrecator ® 2000 Electrosurgical System, Observation Alone
- Where
- 4 sites in Canada
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Obesity
Beta-glucan and Insulin Sensitivity in Obese Humans
Obesity is an important health problem of modern civilization. In Western societies, almost half of the adult population has problems with an increased body weight.
- Trial name
- NCT01393210
- Testing
- low calorie diet plus beta-glucan, low-calorie diet
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Marek Straczkowski
Human Immunodeficiency Virus (HIV)
A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients
This is a triple cohort, open-label pilot study of the safety and antiviral activity of a single infusion of autologous CD4+ T cells genetically modified at the CCR5 gene by Zinc Finger Nucleases SB-728mR (ZFN Modified CD4+ T…
- Trial name
- NCT02388594
- Testing
- ZFN Modified CD4+ T Cells, Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Pennsylvania
Human Blood Cell Disorders, Lymphoid, Myeloid and Erythroid Proliferative Disease
Human Blood Cell Disorders Tissue Bank
The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative…
- Trial name
- NCT00902447
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Hemodialysed Patients With Impaired Liver Enzymes
The Incidence of Occult Hepatitis C Virus Infection in Hemodialysed Patients With Liver Enzymes Disturbances
To assess the incidence of occult hepatitis C virus in hemodialysed patients with mild impairment of liver enzymes
- Trial name
- NCT01054664
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Meir Medical Center
Hepatitis B
Expression of Th9 Cells and Poor/Non-responsiveness to Hepatitis B Vaccination
An observational study will be performed in subjects aged 3-65 years old to describe the dynamic changes of cellular immunity after vaccination of hepatitis B vaccine, and to find out the expression levels of Th9 cells and IL9 in…
- Trial name
- NCT01441609
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Beijing Municipal Science & Technology Commission
Bronchopulmonary Dysplasia
Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
This is a long term follow-up study of the open label, single-center, phase I clinical trial to evaluate the safety of Pneumostem® in premature infants with BPD.
- Trial name
- NCT01632475
- Testing
- Pneumostem®
- Where
- 2 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- Samsung Medical Center
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is a single-center, open clinical study, divided into two phases of dose escalation and dose expansion, to observe the safety and efficacy of RD140 injection at different doses in patients with relapsed/refractory multiple…
- Trial name
- NCT06655519
- Testing
- CAR-T（RD140 injection）
- Volunteers
- 12 people
- Sponsor
- Peking University People's Hospital
Hepatitis B, Chronic
Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®), a new class of bispecific protein therapeutics designed for the treatment of chronic hepatitis B virus (HBV) infection (CHB).
- Trial name
- NCT05867056
- Testing
- IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD
- Where
- 15 sites in United States, Australia and 7 more
- Sponsor
- Immunocore Ltd